Trial · NCT05918068
Pyridoxine Effect on the Blood Glucose Level in Type 2 Diabetic Patients
NCT05918068, Not applicable, Completed, Al-Rasheed University College
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pyridoxine Effect on the Blood Glucose Level in Type 2 Diabetic Patients. Trials, record NCT05918068. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05918068
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pyridoxine Effect on the Blood Glucose Level in Type 2 Diabetic Patients
- NCT number
- NCT05918068
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 108 participants, actual
- Lead sponsor
- Al-Rasheed University College
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Metformin 500 mg/day, Metformin 500 mg/day plus vitamin B6 300 mg/day, non-pharmacological therapy
- First posted
- 2023-06-26
- Last updated
- 2023-06-26
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Fasting plasma glucose (FPG). | Change from baseline, to one month | A fasting plasma glucose test, also known as a fasting glucose test (FGT), is a test that can be used to help diagnose diabetes or pre-diabetes.The expected values for normal fasting blood glucose concentration are between 70 mg/dL (3.9 mmol/L) and 100 mg/dL (5.6 mmol/L). When fasting blood glucose is between 100 to 125 mg/dL (5.6 to 6.9 mmol/L), changes in lifestyle and monitoring glycemia are recommended |
| Primary | Glycated Hemoglobin (HbAlc) | Change from baseline, to one month | A normal A1C level is below 5.7%, a level of 5.7% to 6.4% indicates prediabetes and a level of 6.5% or more indicates diabetes. |
| Secondary | Vitamin B6 | Change from baseline, to one month | The reference range for pyridoxal phosphate (PLP), the biologically active form of vitamin B6, is 5-50 µg/L. |
| Secondary | Fasting plasma insulin (F.P.I.). | Change from baseline, to one month | The insulin fasting blood test is chiefly used to test insulin levels and diagnose diabetes and insulin resistance. |
| Secondary | Insulin resistance (HOMA-IR). | Change from baseline, to one month | Less than 1.0 means you are insulin-sensitive which is optimal. Above 1.9 indicates early insulin resistance. Above 2.9 indicates significant insulin resistance. |
| Secondary | Indoleamine 2,3 dioxygenase (IDO) | Change from baseline, to one month | Has the potential role of indoleamine 2,3 dioxygenase (IDO) as a predictive and therapeutic target for diabetes treatment |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05918068
GET https://conductscience.org/api/trials/v1/NCT05918068/registered